Sign In
Buy AQST
$4.03
+0.100 (+2.54%)
At Close: Jun 03, 2026
Aquestive Therapeutics (AQST) Stock Gains on Positive Data for EpiPen Rival
10:19am, Tuesday, 27'th Sep 2022
Source: Rob Byron / Shutterstock.com Aquestive Therapeutics (NASDAQ: AQST ) stock is taking off on Tuesday as investors react to positive clinical trial data from the pharmaceutical company. Aquestive
Aquestive Therapeutics: Waiting To Buy After FDA Goes Halfway With Libervant
01:38pm, Friday, 02'nd Sep 2022
After 8 months of waiting for an update from the FDA, the agency finally announced a tentative approval for Aquestive's Libervant. Unfortunately, the company cannot market the product. Aquestive Thera
Aquestive Therapeutics to Participate in Two Investor Conferences in September
04:02pm, Wednesday, 31'st Aug 2022
WARREN, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and
How Inflation Impacts Penny Stocks and the Stock Market
11:30am, Saturday, 13'th Aug 2022
Use these tips for trading penny stocks with high inflation The post How Inflation Impacts Penny Stocks and the Stock Market appeared first on Penny Stocks to Buy, Picks, News and Information | Penn
Aquestive Therapeutics, Inc. (AQST) CEO Dan Barber on Q2 2022 Results - Earnings Call Transcript
03:45pm, Wednesday, 03'rd Aug 2022
Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q2 2022 Earnings Conference Call August 3, 2022 8:00 AM ET Company Participants Bennett Watson - ICR Westwicke, Investor Relations Dan Barber - Chief Execut
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
06:51pm, Tuesday, 02'nd Aug 2022
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 12.20% and 32.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceuticals (CPRX) Rallies 43% YTD: Here's Why
04:04pm, Friday, 22'nd Jul 2022 Zacks Investment Research
Catalyst's (CPRX) price rallies on the back of the robust performance of its lead drug, Firdapse, approved for treating LEMS in adults. The company is also trying to launch Firdapse in the internation
Verve (VERV) Up on Gene Editing Collaboration With Vertex
03:34pm, Thursday, 21'st Jul 2022 Zacks Investment Research
Verve Therapeutics (VERV) enters into a four-year collaboration with Vertex Therapeutics to develop a gene-editing program targeted at liver disease for an upfront payment of $60 million.
Marinus (MRNS) to Sell Rare Disease PRV to Novo Nordisk
03:43pm, Friday, 15'th Jul 2022 Zacks Investment Research
Marinus Pharmaceuticals (MRNS) agrees to sell its Rare Pediatric Disease Priority Review Voicer (RPV) to Novo Nordisk for $110 million.
Vaxcyte (PCVX) Completes Enrollment in Pneumococcal Disease Study
03:59pm, Thursday, 14'th Jul 2022 Zacks Investment Research
Vaxcyte (PCVX) enrolls the last patient in the phase II portion of phase I/HH study, evaluating VAX-24 for preventing invasive pneumococcal disease and pneumonia in healthy adults.
Rhythm (RYTM) Surges on Upbeat Data on Lead Product Candidate
04:15pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
Rhythm Pharmaceuticals (RYTM) reports favorable data from a mid-stage study evaluating the efficacy of setmelanotide, its MC4R agonist, for treating hypothalamic obesity.
Pliant Therapeutics (PLRX) Up on Positive Data From Lung Disease Study
03:01pm, Tuesday, 12'th Jul 2022 Zacks Investment Research
Pliant Therapeutics (PLRX) reports favorable data from a mid-stage study, which supports the potential of PLN-74809, its experimental drug candidate for treating IPF.
Aquestive Therapeutics Reports Positive Results from Final Two Arms of EPIPHAST Trial Supporting Performance and Real-World Functionality of AQST-109 Epinephrine Oral Film
12:00pm, Monday, 11'th Jul 2022 GlobeNewswire Inc.
WARREN, N.J., July 11, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care
Intercept (ICPT) Reports Positive Data From NASH Study on OCA
03:12pm, Friday, 08'th Jul 2022 Zacks Investment Research
Intercept (ICPT) reports positive top-line results from a new analysis of its ongoing pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
Intercept (ICPT) Ocaliva Drives Growth, Pipeline Setbacks Hurt
03:23pm, Thursday, 07'th Jul 2022 Zacks Investment Research
Intercept (ICPT) currently has only one marketed product in its portfolio, Ocaliva, for treating PBC. The company continues to evaluate the potential of OCA in treating progressive liver diseases.
